ICON PLC (ICLR) Fundamental Analysis & Valuation

NASDAQ:ICLR • IE0005711209

110.75 USD
+0.55 (+0.5%)
Last: Mar 5, 2026, 02:40 PM

This ICLR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

ICLR gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. ICLR has an average financial health and profitability rating. ICLR scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, ICLR could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. ICLR Profitability Analysis

1.1 Basic Checks

  • ICLR had positive earnings in the past year.
  • ICLR had a positive operating cash flow in the past year.
  • ICLR had positive earnings in each of the past 5 years.
  • Each year in the past 5 years ICLR had a positive operating cash flow.
ICLR Yearly Net Income VS EBIT VS OCF VS FCFICLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • The Return On Assets of ICLR (3.63%) is better than 77.19% of its industry peers.
  • With a decent Return On Equity value of 6.42%, ICLR is doing good in the industry, outperforming 77.19% of the companies in the same industry.
  • ICLR has a better Return On Invested Capital (6.74%) than 78.95% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ICLR is significantly below the industry average of 11.61%.
  • The last Return On Invested Capital (6.74%) for ICLR is above the 3 year average (5.80%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.63%
ROE 6.42%
ROIC 6.74%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ICLR Yearly ROA, ROE, ROICICLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • With a decent Profit Margin value of 7.40%, ICLR is doing good in the industry, outperforming 77.19% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ICLR has declined.
  • Looking at the Operating Margin, with a value of 13.99%, ICLR is in the better half of the industry, outperforming 75.44% of the companies in the same industry.
  • ICLR's Operating Margin has been stable in the last couple of years.
  • With a Gross Margin value of 28.15%, ICLR is not doing good in the industry: 77.19% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
Industry RankSector Rank
OM 13.99%
PM (TTM) 7.4%
GM 28.15%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
ICLR Yearly Profit, Operating, Gross MarginsICLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

5

2. ICLR Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ICLR is destroying value.
  • ICLR has less shares outstanding than it did 1 year ago.
  • ICLR has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ICLR has been reduced compared to a year ago.
ICLR Yearly Shares OutstandingICLR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ICLR Yearly Total Debt VS Total AssetsICLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • ICLR has an Altman-Z score of 1.63. This is a bad value and indicates that ICLR is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 1.63, ICLR perfoms like the industry average, outperforming 54.39% of the companies in the same industry.
  • ICLR has a debt to FCF ratio of 3.53. This is a good value and a sign of high solvency as ICLR would need 3.53 years to pay back of all of its debts.
  • ICLR's Debt to FCF ratio of 3.53 is amongst the best of the industry. ICLR outperforms 80.70% of its industry peers.
  • A Debt/Equity ratio of 0.31 indicates that ICLR is not too dependend on debt financing.
  • ICLR's Debt to Equity ratio of 0.31 is in line compared to the rest of the industry. ICLR outperforms 49.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF 3.53
Altman-Z 1.63
ROIC/WACC0.76
WACC8.81%
ICLR Yearly LT Debt VS Equity VS FCFICLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

  • ICLR has a Current Ratio of 1.06. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
  • ICLR's Current ratio of 1.06 is on the low side compared to the rest of the industry. ICLR is outperformed by 82.46% of its industry peers.
  • ICLR has a Quick Ratio of 1.06. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.06, ICLR is doing worse than 75.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 1.06
ICLR Yearly Current Assets VS Current LiabilitesICLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

4

3. ICLR Growth Analysis

3.1 Past

  • ICLR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.99%.
  • The Earnings Per Share has been growing by 15.23% on average over the past years. This is quite good.
  • The Revenue has decreased by -2.46% in the past year.
  • Measured over the past years, ICLR shows a very strong growth in Revenue. The Revenue has been growing by 24.17% on average per year.
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%

3.2 Future

  • ICLR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.14% yearly.
  • The Revenue is expected to grow by 1.48% on average over the next years.
EPS Next Y-5.37%
EPS Next 2Y-4.18%
EPS Next 3Y0.09%
EPS Next 5Y2.14%
Revenue Next Year-2.67%
Revenue Next 2Y-1.68%
Revenue Next 3Y0.22%
Revenue Next 5Y1.48%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ICLR Yearly Revenue VS EstimatesICLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
ICLR Yearly EPS VS EstimatesICLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

7

4. ICLR Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 8.40 indicates a reasonable valuation of ICLR.
  • 98.25% of the companies in the same industry are more expensive than ICLR, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 27.03, ICLR is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 8.62, the valuation of ICLR can be described as very reasonable.
  • ICLR's Price/Forward Earnings ratio is rather cheap when compared to the industry. ICLR is cheaper than 98.25% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 25.11. ICLR is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 8.4
Fwd PE 8.62
ICLR Price Earnings VS Forward Price EarningsICLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 98.25% of the companies in the same industry are more expensive than ICLR, based on the Enterprise Value to EBITDA ratio.
  • 98.25% of the companies in the same industry are more expensive than ICLR, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 8.77
EV/EBITDA 7.46
ICLR Per share dataICLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

  • The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.55
EPS Next 2Y-4.18%
EPS Next 3Y0.09%

0

5. ICLR Dividend Analysis

5.1 Amount

  • No dividends for ICLR!.
Industry RankSector Rank
Dividend Yield 0%

ICLR Fundamentals: All Metrics, Ratios and Statistics

ICON PLC

NASDAQ:ICLR (3/5/2026, 2:40:52 PM)

110.75

+0.55 (+0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-22
Earnings (Next)04-30
Inst Owners105.53%
Inst Owner Change4.32%
Ins Owners0.66%
Ins Owner ChangeN/A
Market Cap8.46B
Revenue(TTM)8.10B
Net Income(TTM)599.48M
Analysts74.17
Price Target159.5 (44.02%)
Short Float %2.65%
Short Ratio1.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.77%
Min EPS beat(2)-1.21%
Max EPS beat(2)-0.34%
EPS beat(4)1
Avg EPS beat(4)-0.63%
Min EPS beat(4)-1.21%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.34%
EPS beat(12)2
Avg EPS beat(12)-1.79%
EPS beat(16)5
Avg EPS beat(16)-1.4%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-2.61%
Max Revenue beat(4)1.03%
Revenue beat(8)1
Avg Revenue beat(8)-2.24%
Revenue beat(12)1
Avg Revenue beat(12)-2.14%
Revenue beat(16)1
Avg Revenue beat(16)-2.06%
PT rev (1m)-23.67%
PT rev (3m)-23.97%
EPS NQ rev (1m)-2.15%
EPS NQ rev (3m)-2.29%
EPS NY rev (1m)0.01%
EPS NY rev (3m)-0.04%
Revenue NQ rev (1m)-0.49%
Revenue NQ rev (3m)-0.58%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.05%
Valuation
Industry RankSector Rank
PE 8.4
Fwd PE 8.62
P/S 1.04
P/FCF 8.77
P/OCF 7.42
P/B 0.91
P/tB N/A
EV/EBITDA 7.46
EPS(TTM)13.19
EY11.91%
EPS(NY)12.85
Fwd EY11.61%
FCF(TTM)12.63
FCFY11.4%
OCF(TTM)14.93
OCFY13.48%
SpS106.11
BVpS122.25
TBVpS-38.98
PEG (NY)N/A
PEG (5Y)0.55
Graham Number190.47
Profitability
Industry RankSector Rank
ROA 3.63%
ROE 6.42%
ROCE 8.53%
ROIC 6.74%
ROICexc 6.98%
ROICexgc 176.34%
OM 13.99%
PM (TTM) 7.4%
GM 28.15%
FCFM 11.9%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexgc growth 3Y-4.45%
ROICexgc growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score6
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF 3.53
Debt/EBITDA 1.89
Cap/Depr 45.31%
Cap/Sales 2.17%
Interest Coverage 250
Cash Conversion 74.92%
Profit Quality 160.84%
Current Ratio 1.06
Quick Ratio 1.06
Altman-Z 1.63
F-Score6
WACC8.81%
ROIC/WACC0.76
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
EPS Next Y-5.37%
EPS Next 2Y-4.18%
EPS Next 3Y0.09%
EPS Next 5Y2.14%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
Revenue Next Year-2.67%
Revenue Next 2Y-1.68%
Revenue Next 3Y0.22%
Revenue Next 5Y1.48%
EBIT growth 1Y-0.88%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year0.44%
EBIT Next 3Y0.52%
EBIT Next 5Y2.03%
FCF growth 1Y86.71%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y72.39%
OCF growth 3Y15.78%
OCF growth 5Y25.55%

ICON PLC / ICLR FAQ

Can you provide the ChartMill fundamental rating for ICON PLC?

ChartMill assigns a fundamental rating of 5 / 10 to ICLR.


What is the valuation status for ICLR stock?

ChartMill assigns a valuation rating of 7 / 10 to ICON PLC (ICLR). This can be considered as Undervalued.


How profitable is ICON PLC (ICLR) stock?

ICON PLC (ICLR) has a profitability rating of 6 / 10.


What is the valuation of ICON PLC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ICON PLC (ICLR) is 8.4 and the Price/Book (PB) ratio is 0.91.


How financially healthy is ICON PLC?

The financial health rating of ICON PLC (ICLR) is 5 / 10.